{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T04:13:54Z","timestamp":1790828034495,"version":"4.1.0"},"reference-count":117,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"am","delay-in-days":542,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01 AI142135"],"award-info":[{"award-number":["1R01 AI142135"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seminarsinnephrology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Nephrology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.semnephrol.2024.151503","type":"journal-article","created":{"date-parts":[[2024,3,22]],"date-time":"2024-03-22T06:00:48Z","timestamp":1711087248000},"page":"151503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Post-Transplant Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"44","author":[{"given":"Vikas R.","family":"Dharnidharka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna B.","family":"Ruzinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianna J.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semnephrol.2024.151503_bib0001","doi-asserted-by":"crossref","first-page":"15088","DOI":"10.1038\/nrdp.2015.88","article-title":"Post-transplant lymphoproliferative disorders","volume":"2","author":"Dharnidharka","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0002","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1702693","article-title":"Post-transplantation lymphoproliferative disorders in adults","volume":"378","author":"Dierickx","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0003","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.3389\/ti.2022.10024","article-title":"Incidence and outcomes of early cancers after kidney transplantation","volume":"35","author":"Krishnan","year":"2022","journal-title":"Transpl Int"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0004","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/ajt.14603","article-title":"Comprehensive review of post-organ transplant hematologic cancers","volume":"18","author":"Dharnidharka","year":"2018","journal-title":"Am J Transplant"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151503_bib0005","doi-asserted-by":"crossref","first-page":"e13652","DOI":"10.1111\/ctr.13652","article-title":"Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice","volume":"33","author":"Allen","year":"2019","journal-title":"Clin Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151503_bib0006","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/TP.0b013e318270bc7b","article-title":"Posttransplant malignancies in solid organ adult recipients: an analysis of the U.S. National Transplant Database","volume":"94","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0007","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1097\/TP.0b013e318276a237","article-title":"Epidemiology of posttransplantation lymphoproliferative disorder in adult renal transplant recipients","volume":"95","author":"Morton","year":"2013","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0008","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfx356","article-title":"Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study","volume":"33","author":"Francis","year":"2018","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0009","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1007\/s00467-007-0582-3","article-title":"Post-transplant lymphoproliferative disease","volume":"24","author":"Dharnidharka","year":"2009","journal-title":"Pediatr Nephrol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0010","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1056\/NEJMra1314376","article-title":"Kidney transplantation in children","volume":"371","author":"Dharnidharka","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0011","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ajt.2023.02.014","article-title":"Mutations in latent membrane protein 1 of Epstein-Barr virus are associated with increased risk of posttransplant lymphoproliferative disorder in children","volume":"23","author":"Martinez","year":"2023","journal-title":"Am J Transplant"},{"issue":"17","key":"10.1016\/j.semnephrol.2024.151503_bib0012","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0013","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1111\/j.1600-6143.2007.01972.x","article-title":"Dissociation of depletional induction and posttransplant lymphoproliferative disease in kidney recipients treated with alemtuzumab","volume":"7","author":"Kirk","year":"2007","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0014","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/j.1600-6143.2011.03893.x","article-title":"Associations between EBV serostatus and organ transplant type in PTLD risk: an analysis of the SRTR national registry data in the United States","volume":"12","author":"Dharnidharka","year":"2012","journal-title":"Am J Transplant"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151503_bib0015","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am J Transplant"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0016","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0017","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1432-2277.2003.tb00343.x","article-title":"A single-centre experience of post-renal transplant lymphoproliferative disorder","volume":"16","author":"Herzig","year":"2003","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0018","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"issue":"25","key":"10.1016\/j.semnephrol.2024.151503_bib0019","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJM199012203232502","article-title":"Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients","volume":"323","author":"Swinnen","year":"1990","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151503_bib0020","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1097\/TP.0b013e3182007b95","article-title":"An integrated safety profile analysis of belatacept in kidney transplant recipients","volume":"90","author":"Grinyo","year":"2010","journal-title":"Transplantation"},{"issue":"4 Pt 1","key":"10.1016\/j.semnephrol.2024.151503_bib0021","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1111\/j.1600-6143.2005.00776.x","article-title":"Analysis of factors that influence survival with post-transplant lymphoproliferative disorder in renal transplant recipients: the Israel Penn International Transplant Tumor Registry experience","volume":"5","author":"Trofe","year":"2005","journal-title":"Am J Transplant"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0022","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1111\/j.1600-6143.2006.01540.x","article-title":"Post-transplant lymphoproliferative disorders occurring after renal transplantation in adults: report of 230 cases from the French Registry","volume":"6","author":"Caillard","year":"2006","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0023","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/ajt.14020","article-title":"The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients: a systematic review","volume":"17","author":"AlDabbagh","year":"2017","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0024","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1111\/tri.13085","article-title":"Impact of antiviral prophylaxis in adults Epstein-Barr virus-seronegative kidney recipients on early and late post-transplantation lymphoproliferative disorder onset: a retrospective cohort study","volume":"31","author":"Ville","year":"2018","journal-title":"Transpl Int"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0025","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1034\/j.1399-3062.2001.003002060.x","article-title":"The Epstein-Barr virus and post-transplant lymphoproliferative disease: interplay of immunosuppression, EBV, and the immune system in disease pathogenesis","volume":"3","author":"Tanner","year":"2001","journal-title":"Transpl Infect Dis"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0026","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1600-6143.2011.03499.x","article-title":"Epstein-Barr virus-related post-transplant lymphoproliferative disorders: pathogenetic insights for targeted therapy","volume":"11","author":"Nourse","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0027","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N Engl J Med"},{"issue":"Pt 1","key":"10.1016\/j.semnephrol.2024.151503_bib0028","first-page":"151","article-title":"EBV persistence\u2014introducing the virus","volume":"390","author":"Thorley-Lawson","year":"2015","journal-title":"Curr Top Microbiol Immunol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0029","doi-asserted-by":"crossref","first-page":"e131","DOI":"10.1038\/emm.2014.84","article-title":"Epstein-Barr virus latent genes","volume":"47","author":"Kang","year":"2015","journal-title":"Exp Mol Med"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151503_bib0030","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1172\/JCI24810","article-title":"Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance","volume":"115","author":"Hislop","year":"2005","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151503_bib0031","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","article-title":"Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein-Barr virus in vivo","volume":"187","author":"Callan","year":"1998","journal-title":"J Exp Med"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0032","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/ajt.12196","article-title":"Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders","volume":"13","author":"Morscio","year":"2013","journal-title":"Am J Transplant"},{"issue":"13","key":"10.1016\/j.semnephrol.2024.151503_bib0033","doi-asserted-by":"crossref","first-page":"e00238","DOI":"10.1128\/JVI.00238-19","article-title":"Mechanisms of B-cell oncogenesis induced by Epstein-Barr virus","volume":"93","author":"Saha","year":"2019","journal-title":"J Virol"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0034","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0898-6568(02)00083-9","article-title":"CD40 and its viral mimic, LMP1: similar means to different ends","volume":"15","author":"Lam","year":"2003","journal-title":"Cell Signal"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0035","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1038\/sj.onc.1209023","article-title":"LMP1 signaling and activation of NF-kappaB in LMP1 transgenic mice","volume":"25","author":"Thornburg","year":"2006","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0036","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.celrep.2014.07.037","article-title":"The NF-kappaB genomic landscape in lymphoblastoid B cells","volume":"8","author":"Zhao","year":"2014","journal-title":"Cell Rep"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0037","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1128\/JVI.73.2.1023-1035.1999","article-title":"Epstein-Barr virus-encoded latent membrane protein 1 activates the JNK pathway through its extreme C terminus via a mechanism involving TRADD and TRAF2","volume":"73","author":"Eliopoulos","year":"1999","journal-title":"J Virol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0038","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1093\/emboj\/18.11.3064","article-title":"Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins","volume":"18","author":"Gires","year":"1999","journal-title":"EMBO J"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0039","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0092-8674(95)90489-1","article-title":"The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family","volume":"80","author":"Mosialos","year":"1995","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0040","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1074\/jbc.M209840200","article-title":"Epstein-Barr virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase\/Akt pathway to promote cell survival and induce actin filament remodeling","volume":"278","author":"Dawson","year":"2003","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151503_bib0041","doi-asserted-by":"crossref","first-page":"8225","DOI":"10.4049\/jimmunol.179.12.8225","article-title":"Latent membrane protein 1 of EBV activates phosphatidylinositol 3-kinase to induce production of IL-10","volume":"179","author":"Lambert","year":"2007","journal-title":"J Immunol"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151503_bib0042","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1097\/TP.0000000000001767","article-title":"The immune response to Epstein Barr virus and implications for posttransplant lymphoproliferative disorder","volume":"101","author":"Martinez","year":"2017","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0043","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.cell.2011.12.031","article-title":"Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model","volume":"148","author":"Zhang","year":"2012","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0044","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1002\/cam4.1985","article-title":"Metagenomic analysis of DNA viruses from posttransplant lymphoproliferative disorders","volume":"8","author":"Dharnidharka","year":"2019","journal-title":"Cancer Med"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0045","doi-asserted-by":"crossref","first-page":"e131644","DOI":"10.1172\/jci.insight.131644","article-title":"Genomic variations in EBNA3C of EBV associate with posttransplant lymphoproliferative disorder","volume":"5","author":"Maloney","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0046","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1111\/ajt.13324","article-title":"The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder","volume":"15","author":"Luskin","year":"2015","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0047","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0048","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2","first-page":"453","article-title":"Immunodeficiency-associated lymphoproliferative disorders","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0049","unstructured":"Swerdlow SH, Craig FE. Iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Jaffe ES, Harris NL, Vardiman JW, eds. Hematopathology. Elsevier Saunders; 2016:1013-1025."},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0050","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/sj.leu.2401390","article-title":"Primary effusion lymphoma after heart transplantation: a new entity associated with human herpesvirus-8","volume":"13","author":"Dotti","year":"1999","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0051","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00000478-199911000-00010","article-title":"Posttransplantation plasmacytic proliferations related to Kaposi's sarcoma-associated herpesvirus","volume":"23","author":"Matsushima","year":"1999","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0052","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/ajt.13558","article-title":"EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcriptomic features","volume":"16","author":"Ferreiro","year":"2016","journal-title":"Am J Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0053","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/PDM.0b013e31804f54a9","article-title":"Gene expression profiling of Epstein-Barr virus-positive and -negative monomorphic B-cell posttransplant lymphoproliferative disorders","volume":"16","author":"Craig","year":"2007","journal-title":"Diagn Mol Pathol"},{"issue":"13","key":"10.1016\/j.semnephrol.2024.151503_bib0054","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1182\/bloodadvances.2022009521","article-title":"Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS","volume":"7","author":"Guney","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0055","first-page":"106","article-title":"Malignant lymphomas in transplantation patients","volume":"1","author":"Penn","year":"1969","journal-title":"Transplant Proc"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0056","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.semnephrol.2024.151503_bib0057","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.semnephrol.2024.151503_bib0058","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1038\/modpathol.2016.130","article-title":"EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations","volume":"29","author":"Courville","year":"2016","journal-title":"Mod Pathol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0059","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of mature lymphoid neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0060","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0061","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ajcp\/aqw214","article-title":"EBV-positive B-cell proliferations of varied malignant potential: 2015 SH\/EAHP workshop report\u2014part 1","volume":"147","author":"Natkunam","year":"2017","journal-title":"Am J Clin Pathol"},{"issue":"18","key":"10.1016\/j.semnephrol.2024.151503_bib0062","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1182\/blood-2018-04-842559","article-title":"Immunodeficiency-associated lymphoproliferative disorders: time for reappraisal?","volume":"132","author":"Natkunam","year":"2018","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0063","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-022-01764-1","article-title":"A comparison of the International Consensus and 5th World Health Organization classifications of mature B-cell lymphomas","volume":"37","author":"Falini","year":"2023","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0064","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1399-0012.2012.01608.x","article-title":"Quantitative Epstein-Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder","volume":"26","author":"Holman","year":"2012","journal-title":"Clin Transplant"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0065","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/ajt.13982","article-title":"Peripheral blood Epstein-Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk","volume":"17","author":"Dharnidharka","year":"2017","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0066","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-6143.2008.02514.x","article-title":"Interlaboratory comparison of Epstein-Barr virus viral load assays","volume":"9","author":"Preiksaitis","year":"2009","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0067","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcv.2010.03.016","article-title":"EBV viral load detection in clinical virology","volume":"48","author":"Gartner","year":"2010","journal-title":"J Clin Virol"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151503_bib0068","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/ctr.12473","article-title":"Multicenter comparison of laboratory performance in cytomegalovirus and Epstein-Barr virus viral load testing using international standards","volume":"28","author":"Rychert","year":"2014","journal-title":"Clin Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0069","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1309\/AJCP9WYEXKOL9YUV","article-title":"Pattern analysis of Epstein-Barr virus viremia and its significance in the evaluation of organ transplant patients suspected of having posttransplant lymphoproliferative disorders","volume":"141","author":"Cho","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0070","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1097\/TP.0b013e3181b9d918","article-title":"A phase I trial of Epstein-Barr virus gp350 vaccine for children with chronic kidney disease awaiting transplantation","volume":"88","author":"Rees","year":"2009","journal-title":"Transplantation"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0071","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(07)70040-2","article-title":"Effect of cytomegalovirus prophylaxis with immunoglobulin or with antiviral drugs on post-transplant non-Hodgkin lymphoma: a multicentre retrospective analysis","volume":"8","author":"Opelz","year":"2007","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0072","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1111\/j.1600-6143.2006.01394.x","article-title":"CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients","volume":"6","author":"Green","year":"2006","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0073","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1432-2277.2012.01485.x","article-title":"(Val-)ganciclovir prophylaxis reduces Epstein-Barr virus primary infection in pediatric renal transplantation","volume":"25","author":"Hocker","year":"2012","journal-title":"Transpl Int"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0074","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1111\/j.1600-6143.2011.03478.x","article-title":"Monitoring infection with Epstein-Barr virus among seromismatch adult renal transplant recipients","volume":"11","author":"Martin","year":"2011","journal-title":"Am J Transplant"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0075","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/ajt.16423","article-title":"Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study","volume":"21","author":"Walti","year":"2021","journal-title":"Am J Transplant"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0076","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1600-6143.2010.03387.x","article-title":"Reduction of immunosuppression as initial therapy for posttransplantation lymphoproliferative disorder(\u2605)","volume":"11","author":"Reshef","year":"2011","journal-title":"Am J Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0077","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/10428194.2020.1861266","article-title":"Reduction of immunosuppression for post-transplant lymphoproliferative disorder (PTLD): a single-center experience of allograft survival outcomes","volume":"62","author":"Pan","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"10.1016\/j.semnephrol.2024.151503_bib0078","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1111\/j.1600-6143.2005.01098.x","article-title":"Effect of anti-CD 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)","volume":"5","author":"Oertel","year":"2005","journal-title":"Am J Transplant"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0079","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/cncr.21391","article-title":"Rituximab therapy is effective for posttransplant lymphoproliferative disorders after solid organ transplantation: results of a phase II trial","volume":"104","author":"Blaes","year":"2005","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0080","doi-asserted-by":"crossref","first-page":"3053","DOI":"10.1182\/blood-2005-01-0377","article-title":"Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study","volume":"107","author":"Choquet","year":"2006","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0081","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3324\/haematol.11360","article-title":"Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease","volume":"92","author":"Gonzalez-Barca","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0082","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s00277-020-04056-9","article-title":"Long-term follow-up of a prospective phase 2 clinical trial of extended treatment with rituximab in patients with B cell post-transplant lymphoproliferative disease and validation in real world patients","volume":"100","author":"Gonzalez-Barca","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0083","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2016.69.3564","article-title":"Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial","volume":"35","author":"Trappe","year":"2017","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0084","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/ejh.12904","article-title":"DA-EPOCH-R for post-transplant lymphoproliferative disorders","volume":"99","author":"DeStefano","year":"2017","journal-title":"Eur J Haematol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0085","doi-asserted-by":"crossref","first-page":"e29126","DOI":"10.1002\/pbc.29126","article-title":"Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: short-course EPOCH regimens are safe and effective","volume":"68","author":"Rubinstein","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"27","key":"10.1016\/j.semnephrol.2024.151503_bib0086","doi-asserted-by":"crossref","first-page":"6481","DOI":"10.1200\/JCO.2005.08.074","article-title":"Low-dose chemotherapy for Epstein-Barr virus-positive post-transplantation lymphoproliferative disease in children after solid organ transplantation","volume":"23","author":"Gross","year":"2005","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.semnephrol.2024.151503_bib0087","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1111\/j.1600-6143.2012.04206.x","article-title":"Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group report","volume":"12","author":"Gross","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0088","doi-asserted-by":"crossref","first-page":"4468","DOI":"10.1182\/blood.V124.21.4468.4468","article-title":"Response-adapted sequential immuno-chemotherapy of post-transplant lymphoproliferative disorders in pediatric solid organ transplant recipients: results from the prospective Ped-PTLD 2005 trial","volume":"124","author":"Maecker-Kolhoff","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0089","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/ajh.24346","article-title":"Hodgkin lymphoma post-transplant lymphoproliferative disorder: a comparative analysis of clinical characteristics, prognosis, and survival","volume":"91","author":"Rosenberg","year":"2016","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0090","doi-asserted-by":"crossref","first-page":"e27803","DOI":"10.1002\/pbc.27803","article-title":"Treatment and outcomes in classic Hodgkin lymphoma post-transplant lymphoproliferative disorder in children","volume":"66","author":"Twist","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0091","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/pbc.21072","article-title":"Pediatric T-cell post-transplant lymphoproliferative disorder after solid organ transplantation","volume":"50","author":"Yang","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0092","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1309\/LYXN3RGF7D7KPYG0","article-title":"T-cell and NK-cell posttransplantation lymphoproliferative disorders","volume":"127","author":"Swerdlow","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0093","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1111\/ajt.12211","article-title":"Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era","volume":"13","author":"Evens","year":"2013","journal-title":"Am J Transplant"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0094","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/bjh.17398","article-title":"Primary post-transplant lymphoproliferative disorder of the central nervous system: characteristics, management and outcome in 25 paediatric patients","volume":"193","author":"Taj","year":"2021","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.semnephrol.2024.151503_bib0095","doi-asserted-by":"crossref","first-page":"2942","DOI":"10.1182\/blood-2006-05-021782","article-title":"Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)","volume":"108","author":"Savoldo","year":"2006","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0096","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2006-12-063008","article-title":"Allogeneic cytotoxic T-cell therapy for EBV-positive posttransplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial","volume":"110","author":"Haque","year":"2007","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.semnephrol.2024.151503_bib0097","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1182\/blood.2020005466","article-title":"EBV+ lymphoproliferative diseases: opportunities for leveraging EBV as a therapeutic target","volume":"139","author":"Toner","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.semnephrol.2024.151503_bib0098","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1172\/JCI121127","article-title":"Off-the-shelf EBV-specific T cell immunotherapy for rituximab-refractory EBV-associated lymphoma following transplantation","volume":"130","author":"Prockop","year":"2020","journal-title":"J Clin Invest"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0099","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1600-6143.2005.00854.x","article-title":"Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells","volume":"5","author":"Comoli","year":"2005","journal-title":"Am J Transplant"},{"issue":"18","key":"10.1016\/j.semnephrol.2024.151503_bib0100","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1182\/blood.2020008759","article-title":"Safety of CAR T-cell therapy in kidney transplant recipients","volume":"137","author":"Mamlouk","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.semnephrol.2024.151503_bib0101","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1182\/blood-2021-149786","article-title":"Real world evidence (RWE) of safety, efficacy, and outcomes of CD19 CAR-T therapy in 20 patients with solid organ transplant (SOT)-related post-transplant lymphoproliferative disorder (PTLD)","volume":"138","author":"Liu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0102","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"27","key":"10.1016\/j.semnephrol.2024.151503_bib0103","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0104","doi-asserted-by":"crossref","first-page":"771","DOI":"10.3324\/haematol.2012.074500","article-title":"The accuracy of positron emission tomography in the detection of posttransplant lymphoproliferative disorder","volume":"98","author":"Dierickx","year":"2013","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0105","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1111\/j.1600-6143.2006.01459.x","article-title":"PTLD visualization by FDG-PET: improved detection of extranodal localizations","volume":"6","author":"Bakker","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1016\/j.semnephrol.2024.151503_bib0106","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.critrevonc.2018.09.007","article-title":"Performance of advanced imaging modalities at diagnosis and treatment response evaluation of patients with post-transplant lymphoproliferative disorder: a systematic review and meta-analysis","volume":"132","author":"Montes de Jesus","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"14","key":"10.1016\/j.semnephrol.2024.151503_bib0107","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin's lymphoma","volume":"329","year":"1993","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semnephrol.2024.151503_bib0108","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00277-007-0298-2","article-title":"Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with caution","volume":"86","author":"Choquet","year":"2007","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0109","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1200\/JCO.2001.19.3.772","article-title":"Identification of prognostic factors in 61 patients with posttransplantation lymphoproliferative disorders","volume":"19","author":"Leblond","year":"2001","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.semnephrol.2024.151503_bib0110","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2005.01.0934","article-title":"Prognostic analysis for survival in adult solid organ transplant recipients with post-transplantation lymphoproliferative disorders","volume":"23","author":"Ghobrial","year":"2005","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semnephrol.2024.151503_bib0111","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07149.x","article-title":"A new prognosticator for post-transplant lymphoproliferative disorders after renal transplantation","volume":"141","author":"Hourigan","year":"2008","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0112","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1111\/ajt.13086","article-title":"International Prognostic Index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial","volume":"15","author":"Trappe","year":"2015","journal-title":"Am J Transplant"},{"issue":"31","key":"10.1016\/j.semnephrol.2024.151503_bib0113","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1200\/JCO.2006.10.2392","article-title":"CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation","volume":"25","author":"Maecker","year":"2007","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.semnephrol.2024.151503_bib0114","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1600-6143.2011.03470.x","article-title":"Improved survival with recent post-transplant lymphoproliferative disorder (PTLD) in children with kidney transplants","volume":"11","author":"Dharnidharka","year":"2011","journal-title":"Am J Transplant"},{"issue":"1","key":"10.1016\/j.semnephrol.2024.151503_bib0115","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/cid\/cis823","article-title":"Epidemiology and morbidity of Epstein-Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study","volume":"56","author":"Hocker","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.semnephrol.2024.151503_bib0116","doi-asserted-by":"crossref","first-page":"e13151","DOI":"10.1111\/petr.13151","article-title":"Pediatric renal transplantation: a retrospective single-center study on epidemiology and morbidity due to EBV","volume":"22","author":"Laurent","year":"2018","journal-title":"Pediatr Transplant"},{"issue":"5","key":"10.1016\/j.semnephrol.2024.151503_bib0117","doi-asserted-by":"crossref","first-page":"e13747","DOI":"10.1111\/petr.13747","article-title":"Post-transplant lymphoproliferative disorder risk factors in children: analysis of a 23-year single-institutional experience","volume":"24","author":"Bosse","year":"2020","journal-title":"Pediatr Transplant"}],"container-title":["Seminars in Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0270929524000202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T10:51:47Z","timestamp":1748343107000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0270929524000202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":117,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0270929524000202"],"URL":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151503","relation":{},"ISSN":["0270-9295"],"issn-type":[{"value":"0270-9295","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Post-Transplant Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Seminars in Nephrology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semnephrol.2024.151503","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"151503"}}